Manufacturer
PATHEON INC(CANADA)
Registraction Number
MAL24126001ACRZ
Content:
Each capsule contains:
-Mavacamten: 2.5 mg
Indications:
-Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM): Used for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms.
Instructions:
-Dosage: The recommended starting dose is 5 mg orally once daily without regard to food. The dose may be adjusted based on the patient's response, with allowable subsequent doses of 2.5 mg, 5 mg, 10 mg, or 15 mg once daily. The maximum recommended dose is 15 mg orally once daily.
-Administration: Swallow the capsule whole. Do not break, open, or chew the capsule. Take KOPOZGO exactly as your healthcare provider tells you to take it.
Malaysia
